Immunology

COVID-19 Impacts: Allergy Diagnostics Market will Accelerate at a CAGR of almost 13% through 2020-2024 | Expansion of Product Ranges Through M&A to Boost Growth | Technavio

Medical devices, Health, Medical specialties, Medicine, Clinical medicine, RTT, Allergy, Immune system, Immunology, Benchmarking
Friday, August 7, 2020 - 4:30pm

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43789

Key Points: 
  • To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43789
    Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.
  • Our allergy diagnostics market report covers the following areas:
    This study identifies increasing funding for allergy diagnostic devices as one of the prime reasons driving the allergy diagnostics market growth during the next few years.
  • Backed with competitive intelligence and benchmarking, our research reports on the allergy diagnostics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Medical specialties, Life sciences, RTT, Health, Respiratory diseases, Allergy, Immune system, Immunology, Wedbush Securities, Biopharmaceutical, Food allergy
Friday, August 7, 2020 - 1:00pm

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 10:55 a.m. E.T.

Key Points: 
  • Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 10:55 a.m. E.T.
  • A live webcast of the presentation will be accessible in the Investor Relations section of the Aimmune website at www.aimmune.com .
  • Aimmune Therapeutics, Inc. is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies.
  • With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies.

Y-mAbs Announces Second Quarter 2020 Financial Results and Recent Corporate Developments

Life sciences, Biotechnology, Health, Articles, Pharmaceutical industry, Immune system, Immunology, Monoclonal antibody, Biopharmaceutical, MAbs
Thursday, August 6, 2020 - 9:01pm

NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter 2020.

Key Points: 
  • NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter 2020.
  • We are very pleased with our second quarter 2020 financial results, especially seen in conjunction with the recent completion of our omburtamab BLA submission to the FDA.
  • We were very pleased to designate the first four SADA constructs for preclinical development and hope to file the first IND next year.
  • The Company will host a conference call on Friday, August 7, 2020 at 9 am eastern time.

Novateur Ventures explores new strategy to reduce the hyperinflammatory response caused by COVID-19

Organic compounds, Medical specialties, Chemical compounds, Immunology, Eicosanoids, Leukotriene antagonists, Leukotriene, Polyenes, Zileuton, Montelukast, Coronavirus disease, Inflammation
Thursday, August 6, 2020 - 5:23pm

VANCOUVER, British Columbia, Aug. 06, 2020 (GLOBE NEWSWIRE) -- A novel strategy has been developed by Novateur Ventures , which provides new hope in battle against COVID-19.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 06, 2020 (GLOBE NEWSWIRE) -- A novel strategy has been developed by Novateur Ventures , which provides new hope in battle against COVID-19.
  • The study titled A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes was published in Frontiers in Pharmacology , a leading peer-reviewed journal.
  • The strategy co-authored by Ali Ardakani, Founder & Managing Director at Novateur Ventures, and Dr. Colin D. Funk (Queen's University, Kingston) analyzes lipid mediators, known as leukotrienes, as the cause for hyperinflammatory response manifested in severe COVID-19 cases.
  • The proposed zileuton/montelukast combination could readily be added in this setting, with the goal to switch off the hyper-inflammatory response.

Asthma and Allergy Foundation of America (AAFA) Appoints Melanie Carver Chief Mission Officer

Medical specialties, Immunology, Medicine, Asthma and Allergy Foundation of America, AAFA, Asthma and Allergy Friendly, Allergy, Carver
Thursday, August 6, 2020 - 1:53pm

Washington, D.C., Aug. 06, 2020 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) is excited to announce Melanie Carver has been named Chief Mission Officer of the organization.

Key Points: 
  • Washington, D.C., Aug. 06, 2020 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) is excited to announce Melanie Carver has been named Chief Mission Officer of the organization.
  • As Chief Mission Officer, Carver will continue to lead AAFAs programmatic work as a community-focused organization.Included in that community focus, she will oversee AAFAs community outreach, marketing and communications, education, and asthma & allergy friendly Certification Program relations.
  • Melanie is the North Star of everything AAFA does and she is a part of the asthma and allergy community herself.
  • Carver is also playing a leading role in the organizations response to the COVID-19 pandemic, addressing asthma and allergy concerns.

Y-mAbs Announces Completion of Submission of Omburtamab Biologics License Application to FDA

Medical specialties, Clinical medicine, Organ systems, Immune system, Immunology, Immune checkpoint, Neuroblastoma, Monoclonal antibody, C-Met
Thursday, August 6, 2020 - 2:00pm

Omburtamab is an investigational, monoclonal antibody that targets B7-H3, an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types.

Key Points: 
  • Omburtamab is an investigational, monoclonal antibody that targets B7-H3, an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types.
  • The omburtamab BLA is for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma.
  • I am excited to see the completion of Y-mAbs second BLA submission this year in neuroblastoma.
  • Researchers at Memorial Sloan Kettering Cancer Center (MSK) developed omburtamab, which is exclusively licensed by MSK to Y-mAbs.

SAB Biotherapeutics Awarded $35.6M from U.S. Department of Defense for COVID-19 and Scaling Rapid Response Antibody Program

Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Genetics, Clinical trials, Branches of biology, Immunology, Clinical medicine, Medicine, Glycoproteins, Immune system, Biotechnology, Antibody, Polyclonal antibodies, Immunotherapy
Thursday, August 6, 2020 - 1:23pm

Our team is urgently and diligently executing on development and scaling to respond to the current coronavirus pandemic.

Key Points: 
  • Our team is urgently and diligently executing on development and scaling to respond to the current coronavirus pandemic.
  • We filed the Investigational New Drug (IND) application for SAB-185 in just 98 days from the initiation of the program, said Eddie J. Sullivan, co-founder, president and CEO of SAB Biotherapeutics.
  • About the DiversitAb Rapid Response Antibody Program:
    The Rapid Response Antibody Program was initiated as a $27 million progressive and competitive three-stage rapid response contract awarded by the U.S. Department of Defense (DoD).
  • SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies.

Seattle Genetics Achieves Milestone Payment Under Antibody-Drug Conjugate Collaboration with GlaxoSmithKline Triggered by BLENREP (belantamab mafodotin-blmf) FDA Approval

Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical trials, Medical specialties, Clinical medicine, Medicine, Immunology, Monoclonal antibodies, Biotechnology, Seattle Genetics, Antibody-drug conjugates, Antibody-drug conjugate, Antibody, B-cell maturation antigen, Vorsetuzumab mafodotin
Thursday, August 6, 2020 - 1:00pm

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced U.S. Food and Drug Administration (FDA) approval of GlaxoSmithKlines (GSK) BLENREP (belantamab mafodotin-blmf), an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) that utilizes Seattle Genetics proprietary technology.

Key Points: 
  • Seattle Genetics, Inc. (Nasdaq:SGEN) today announced U.S. Food and Drug Administration (FDA) approval of GlaxoSmithKlines (GSK) BLENREP (belantamab mafodotin-blmf), an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) that utilizes Seattle Genetics proprietary technology.
  • The approval triggers a $20 million milestone payment and entitles Seattle Genetics to royalties on BLENREP product sales.
  • Seattle Genetics ADC technology combines the specificity of monoclonal antibodies, innovative linker systems and potent cell-killing agents to treat cancer.
  • Seattle Genetics is entitled to receive fees, progress-dependent milestone payments and royalties on worldwide net sales of any resulting ADC products.

Cabaletta Bio Reports Second Quarter 2020 Financial Results and Provides Business Update 

Immune system, Immunology, T cell, Cabaletta
Thursday, August 6, 2020 - 12:30pm

PHILADELPHIA, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced financial results for the second quarter ended June 30, 2020 and provided a business update.

Key Points: 
  • PHILADELPHIA, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced financial results for the second quarter ended June 30, 2020 and provided a business update.
  • In May 2020, in vivotarget engagement data was presented at the American Academy of Neurology 2020 Science Highlights Virtual Platform.
  • Cabaletta expects to initiate validation of cell processing for MuSK-CAART clinical trials with a commercial grade contract manufacturing partner in the second half of 2020.
  • Cabaletta will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 10, 2020 at 1:00 p.m.

Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis

Medical specialties, Health, Medicine, Breakthrough therapy, Ofatumumab, Immunosuppressants, Sanofi, Immunology, Novartis, Multiple sclerosis, Teriflunomide, Monoclonal antibody
Wednesday, August 5, 2020 - 10:02pm

Regulatory approval for ofatumumab in the US is expected in September 2020 and in Europe by Q2 2021.

Key Points: 
  • Regulatory approval for ofatumumab in the US is expected in September 2020 and in Europe by Q2 2021.
  • Novartis is committed to bringing ofatumumab to patients worldwide and additional regulatory filings are currently underway.
  • Onset of B-cell depletion with subcutaneous administration of ofatumumab in relapsing multiple sclerosis: results from the APLIOS bioequivalence study.
  • Ofatumumab versus teriflunomide in relapsing multiple sclerosis: baseline characteristics of two pivotal phase 3 trials (ASCLEPIOS I and ASCLEPIOS II).